3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Solid Tumor
1
Neoplasms
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
58
Cisplatin
41
Capecitabine
27
Oxaliplatin
25
durvalumab
16
Fluorouracil
16
Leucovorin
15
S 1 (combination)
11
lenvatinib
10
Nivolumab
10
Irinotecan
10
pembrolizumab
8
apatinib
8
Immune Checkpoint Inhibitors
7
130-nm albumin-bound paclitaxel
7
tremelimumab
6
Bevacizumab
6
camrelizumab
5
Trastuzumab
5
Drug Therapy
5
Blood Specimen Collection
5
Albumin-Bound Paclitaxel
5
tislelizumab
4
irinotecan sucrosofate
4
Taxes
4
Liquid Biopsy
4
Folfox protocol
4
toripalimab
3
surufatinib
3
gemcitabine-oxaliplatin regimen
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Biliary Tract Neoplasms
×
ARRY-334543
×
Clear all
NCT03093870
2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3
Completed
151 enrolled
18 charts